Zealand Pharma FIRST LOOK: FY24 results underline pipeline progress
Zealand reported its FY24 results, highlighting significant progress in its pipeline. Key developments include positive results for petrelintide, dapiglutide, and survodutide, with several trials advancing to the next phases in 2025. The company reported a YE24 cash position of $ 1.3bn, supporting accelerated momentum in 2025 with important clinical advancements while it aims to secure a partnership for petrelintide. We reiterate our DKK 970 TPP and Buy rating.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.